{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:54:01Z","timestamp":1770476041980,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2003,5,1]]},"DOI":"10.1038\/sj.leu.2402901","type":"journal-article","created":{"date-parts":[[2003,5,15]],"date-time":"2003-05-15T17:50:08Z","timestamp":1053021008000},"page":"849-855","source":"Crossref","is-referenced-by-count":25,"title":["In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia"],"prefix":"10.1038","volume":"17","author":[{"given":"R A","family":"Mesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L A","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S H","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,5,15]]},"reference":[{"key":"BF2402901_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","volume":"342","author":"A Tefferi","year":"2000","unstructured":"Tefferi A . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255\u20131265.","journal-title":"N Engl J Med"},{"key":"BF2402901_CR2","first-page":"2831","volume":"93","author":"P Guardiola","year":"1999","unstructured":"Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831\u20132838.","journal-title":"Blood"},{"key":"BF2402901_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1182\/blood.V98.3.586","volume":"98","author":"JE Anderson","year":"2001","unstructured":"Anderson JE, Tefferi A, Craig F, Holmberg L, Chauncy T, Appelbaum FR et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 2001; 98: 586\u2013593.","journal-title":"Blood"},{"key":"BF2402901_CR4","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","volume":"95","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN . Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226\u20132233.","journal-title":"Blood"},{"key":"BF2402901_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO;2-4","volume":"49","author":"EC Besa","year":"1982","unstructured":"Besa EC, Nowell PC, Geller NL, Gardner FH . Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982; 49: 308\u2013313.","journal-title":"Cancer"},{"key":"BF2402901_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/(SICI)1096-8652(199612)53:4<239::AID-AJH5>3.0.CO;2-Z","volume":"53","author":"V Levy","year":"1996","unstructured":"Levy V, Bourgarit A, Delmer A, Legrand O, Baudard M, Rio B et al. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol 1996; 53: 239\u2013241.","journal-title":"Am J Hematol"},{"key":"BF2402901_CR7","first-page":"616","volume":"83","author":"JN Rodriguez","year":"1998","unstructured":"Rodriguez JN, Martino ML, Dieguez JC, Prados D . rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 1998; 83: 616\u2013621.","journal-title":"Haematologica"},{"key":"BF2402901_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/10428199509059658","volume":"19","author":"S Sacchi","year":"1995","unstructured":"Sacchi S . The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Leukemia Lymphoma 1995; 19: 13\u201320.","journal-title":"Leukemia Lymphoma"},{"key":"BF2402901_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1365-2141.1991.tb07989.x","volume":"77","author":"A Manoharan","year":"1991","unstructured":"Manoharan A . Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 1991; 77: 252\u2013254.","journal-title":"Br J Haematol"},{"key":"BF2402901_CR10","first-page":"658","volume":"2","author":"M Buschle","year":"1988","unstructured":"Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR . Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 1988; 2: 658\u2013660.","journal-title":"Leukemia"},{"key":"BF2402901_CR11","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood.V78.7.1814.1814","volume":"78","author":"H Kreipe","year":"1991","unstructured":"Kreipe H, Jaquet K, Felgner J, Radzun HJ, Parwaresch MR . Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 1991; 78: 1814\u20131817.","journal-title":"Blood"},{"key":"BF2402901_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2141.1994.tb04970.x","volume":"88","author":"MC Martyre","year":"1994","unstructured":"Martyre MC, Romquin N, Le Bousse-Kerdiles MC, Chevillard S, Benyahia B, Dupriez B et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994; 88: 9\u201316.","journal-title":"Br J Haematol"},{"key":"BF2402901_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1365-2141.1991.tb07952.x","volume":"77","author":"MC Martyre","year":"1991","unstructured":"Martyre MC, Magdelenat H, Bryckaert MC, Laine-Bidron C, Calvo F . Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1991; 77: 80\u201386.","journal-title":"Br J Haematol"},{"key":"BF2402901_CR14","first-page":"116a","volume":"94","author":"F Di Raimondo","year":"1999","unstructured":"Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Stagno F, Sortino G et al. Elevated VEGF serum levels in idiopathic myelofibrosis (abstract). Blood 1999; 94(Suppl.): 116a.","journal-title":"Blood"},{"key":"BF2402901_CR15","first-page":"307","volume":"154","author":"H Castro-Malaspina","year":"1984","unstructured":"Castro-Malaspina H, Jhanwar SC . Properties of myelofibrosis-derived fibroblasts. Prog Clin Biol Res 1984; 154: 307\u2013322.","journal-title":"Prog Clin Biol Res"},{"key":"BF2402901_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2141.2001.02883.x","volume":"114","author":"RA Mesa","year":"2001","unstructured":"Mesa RA, Tefferi A, Elliott MA, Hoagland HC, Call TG, Schroeder GS et al. A phase II trial of pirfenidone (5-methyl1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114: 111\u2013113.","journal-title":"Br J Haematol"},{"key":"BF2402901_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1365-2141.2001.02918.x","volume":"114","author":"G Barosi","year":"2001","unstructured":"Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M . Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114: 78\u201383.","journal-title":"Br J Haematol"},{"key":"BF2402901_CR18","first-page":"626a","volume":"98","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA et al. Gleevec therapy in myelofibrosis with myeloid metaplasia (MMM) (abstract). Blood 2001; 98(Suppl.): 626a.","journal-title":"Blood"},{"key":"BF2402901_CR19","first-page":"628a","volume":"98","author":"DP Steensma","year":"2001","unstructured":"Steensma DP, Mesa RA, Li CY, Gray L, Call T, Hook CC et al. Etanercept palliates constitutional symptoms in myelofibrosis with myeloid metaplasia: results of a pilot study (abstract). Blood 2001; 98(Suppl.): 628a.","journal-title":"Blood"},{"key":"BF2402901_CR20","first-page":"131","volume":"61","author":"DW End","year":"2001","unstructured":"End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61: 131\u2013137.","journal-title":"Cancer Res"},{"key":"BF2402901_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","volume":"65","author":"FL Zhang","year":"1996","unstructured":"Zhang FL, Casey PJ . Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65: 241\u2013269.","journal-title":"Annu Rev Biochem"},{"key":"BF2402901_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev.pharmtox.37.1.143","volume":"37","author":"JB Gibbs","year":"1997","unstructured":"Gibbs JB, Oliff A . The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 1997; 37: 143\u2013166.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BF2402901_CR23","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1200\/JCO.1999.17.3.1071","volume":"17","author":"DM Beaupre","year":"1999","unstructured":"Beaupre DM, Kurzrock R . RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 1999; 17: 1071\u20131079.","journal-title":"J Clin Oncol"},{"key":"BF2402901_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1388-1981(00)00009-3","volume":"1484","author":"M Sinensky","year":"2000","unstructured":"Sinensky M . Recent advances in the study of prenylated proteins. Biochim Biophys Acta 2000; 1484: 93\u2013106.","journal-title":"Biochim Biophys Acta"},{"key":"BF2402901_CR25","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","volume":"17","author":"EK Rowinsky","year":"1999","unstructured":"Rowinsky EK, Windle JJ, Von Hoff DD . Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631\u20133652.","journal-title":"J Clin Oncol"},{"key":"BF2402901_CR26","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jnci\/93.14.1062","volume":"93","author":"AA Adjei","year":"2001","unstructured":"Adjei AA . Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062\u20131074.","journal-title":"J Natl Cancer Inst"},{"key":"BF2402901_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","volume":"75","author":"AM Pendergast","year":"1993","unstructured":"Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al. BCR\u2013ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175\u2013185.","journal-title":"Cell"},{"key":"BF2402901_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/00001622-200111000-00009","volume":"13","author":"JE Karp","year":"2001","unstructured":"Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW . Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol 2001; 13: 470\u2013476.","journal-title":"Curr Opin Oncol"},{"key":"BF2402901_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/00001622-199711000-00011","volume":"9","author":"S Sebti","year":"1997","unstructured":"Sebti S, Hamilton AD . Inhibitors of prenyl transferases. Curr Opin Oncol 1997; 9: 557\u2013561.","journal-title":"Curr Opin Oncol"},{"key":"BF2402901_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1367-5931(98)80034-3","volume":"2","author":"MH Gelb","year":"1998","unstructured":"Gelb MH, Scholten JD, Sebolt-Leopold JS . Protein prenylation: from discovery to prospects for cancer treatment. Curr Opin Chem Biol 1998; 2: 40\u201348.","journal-title":"Curr Opin Chem Biol"},{"key":"BF2402901_CR31","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V69.4.1237.1237","volume":"69","author":"JL Bos","year":"1987","unstructured":"Bos JL, Verlaan-de Vries M, van der Eb AJ, Janssen JW, Delwel R, Lowenberg B et al. Mutations in N-ras predominate in acute myeloid leukemia. Blood 1987; 69: 1237\u20131241.","journal-title":"Blood"},{"key":"BF2402901_CR32","unstructured":"Wright J, Blatner GL, Cheson BD . Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777. Oncology 1999; 13: 1527, 1530, 1533."},{"key":"BF2402901_CR33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2000.18.4.927","volume":"18","author":"J Zujewski","year":"2000","unstructured":"Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000; 18: 927\u2013941.","journal-title":"J Clin Oncol"},{"key":"BF2402901_CR34","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","volume":"97","author":"JE Karp","year":"2001","unstructured":"Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97: 3361\u20133369.","journal-title":"Blood"},{"key":"BF2402901_CR35","first-page":"848a","volume":"98","author":"R Kurzrock","year":"2001","unstructured":"Kurzrock R, Cortes J, Ryback ME, Thibault A, Faderl S, Estey E et al. Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome (abstract). Blood 2001; 98(Suppl.): 848a.","journal-title":"Blood"},{"key":"BF2402901_CR36","first-page":"623a","volume":"98","author":"R Kurzrock","year":"2001","unstructured":"Kurzrock R, Sebti SM, Kantarjian HM, Wright J, Cortes JE, Thomas DA et al. Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome (abstract). Blood 2001; 98(Suppl.): 623a.","journal-title":"Blood"},{"key":"BF2402901_CR37","doi-asserted-by":"publisher","first-page":"727a","DOI":"10.1182\/blood.V98.3.727","volume":"98","author":"D Thomas","year":"2001","unstructured":"Thomas D, Cortes J, O'Brien SM, Garcia Manero G, Kurzrock R, Giles FJ et al. R115777, a farnesyl transferase inhibitor (FTI), has significant anti-leukemia activity in patients with chronic myeloid leukemia (CML) (abstract). Blood 2001; 98(Suppl.): 727a.","journal-title":"Blood"},{"key":"BF2402901_CR38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.V95.2.639","volume":"95","author":"PD Emanuel","year":"2000","unstructured":"Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP . Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 2000; 95: 639\u2013645.","journal-title":"Blood"},{"key":"BF2402901_CR39","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1046\/j.1365-2141.1999.01262.x","volume":"104","author":"G Barosi","year":"1999","unstructured":"Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL et al. The Italian Consensus Conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 1999; 104: 730\u2013737.","journal-title":"Br J Haematol"},{"key":"BF2402901_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0022-1759(74)90109-4","volume":"5","author":"D English","year":"1974","unstructured":"English D, Andersen BR . Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll\u2013Hypaque. J Immunol Methods 1974; 5: 249\u2013252.","journal-title":"J Immunol Methods"},{"key":"BF2402901_CR41","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1517\/13543784.9.12.2767","volume":"9","author":"SM Sebti","year":"2000","unstructured":"Sebti SM, Hamilton AD . Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin Invest Drugs 2000; 9: 2767\u20132782.","journal-title":"Expert Opin Invest Drugs"},{"key":"BF2402901_CR42","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1016\/S0021-9258(17)37680-9","volume":"269","author":"CJ Vlahos","year":"1994","unstructured":"Vlahos CJ, Matter WF, Hui KY, Brown RF . A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241\u20135248.","journal-title":"J Biol Chem"},{"key":"BF2402901_CR43","doi-asserted-by":"publisher","first-page":"27489","DOI":"10.1074\/jbc.270.46.27489","volume":"270","author":"DR Alessi","year":"1995","unstructured":"Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR . PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995; 270: 27489\u201327494.","journal-title":"J Biol Chem"},{"key":"BF2402901_CR44","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3109\/10428199709055584","volume":"24","author":"J Thiele","year":"1997","unstructured":"Thiele J, Kvasnicka HM, Fischer R, Diehl V . Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update. Leukemia Lymphoma 1997; 24: 463\u2013481.","journal-title":"Leukemia Lymphoma"},{"key":"BF2402901_CR45","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","volume":"98","author":"G Barosi","year":"2001","unstructured":"Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001; 98: 3249\u20133255.","journal-title":"Blood"},{"key":"BF2402901_CR46","doi-asserted-by":"publisher","first-page":"627a","DOI":"10.1182\/blood.V98.3.627","volume":"98","author":"RA Mesa","year":"2001","unstructured":"Mesa RA, Kaufmann SH, Schroeder G, Gray L, Li CY, Tefferi A . Clinical correlates of increased circulating myeloid and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia (abstract). Blood 2001; 98(Suppl.): 627a\u2013628a.","journal-title":"Blood"},{"key":"BF2402901_CR47","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1182\/blood.V97.11.3665","volume":"97","author":"RA Mesa","year":"2001","unstructured":"Mesa RA, Li CY, Schroeder G, Tefferi A . Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood 2001; 97: 3665\u20133667.","journal-title":"Blood"},{"key":"BF2402901_CR48","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V82.6.1838.1838","volume":"82","author":"RA Mandanas","year":"1993","unstructured":"Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K et al. Role of p21 RAS in p210 bcr\u2013abl transformation of murine myeloid cells. Blood 1993; 82: 1838\u20131847.","journal-title":"Blood"},{"key":"BF2402901_CR49","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","volume":"13","author":"L Puil","year":"1994","unstructured":"Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. Bcr\u2013Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13: 764\u2013773.","journal-title":"EMBO J"},{"key":"BF2402901_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1365-2141.2000.02145.x","volume":"110","author":"X Sui","year":"2000","unstructured":"Sui X, Krantz SB, Zhao ZJ . Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways. Br J Haematol 2000; 110: 63\u201370.","journal-title":"Br J Haematol"},{"key":"BF2402901_CR51","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood.V98.5.1374","volume":"98","author":"TC Somervaille","year":"2001","unstructured":"Somervaille TC, Linch DC, Khwaja A . Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax. Blood 2001; 98: 1374\u20131381.","journal-title":"Blood"},{"key":"BF2402901_CR52","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1172\/JCI12807","volume":"108","author":"M Milella","year":"2001","unstructured":"Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D et al. Therapeutic targeting of the MEK\/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001; 108: 851\u2013859.","journal-title":"J Clin Invest"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2402901.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402901","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402901.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:16:23Z","timestamp":1648761383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2402901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,1]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5,1]]}},"alternative-id":["BF2402901"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2402901","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,1]]}}}